Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Japan
Biotech
Kaken pens $180M pact for Alumis' lead TYK2 inhibitor in Japan
Kaken will hand Alumis $40 million in the near term for the rights to a late-stage tyrosine kinase 2 inhibitor as a dermatology treatment in Japan.
James Waldron
Mar 25, 2025 6:55am
Eisai pays $46M for Japan rights to Newron's schizophrenia med
Dec 13, 2024 8:37am
GE HealthCare to take over Japanese radiopharmaceutical venture
Dec 2, 2024 2:00pm
Astellas telegraphs new cell therapy site in Japan, 24 US layoffs
Oct 9, 2024 5:45pm
Fujitsu partners with Paradigm to boost clinical trials in Japan
Aug 28, 2024 12:43pm
Medtronic nets Japan approval for pulsed field ablation system
May 13, 2024 11:25am
